IFTBF (Infant Bacterial Therapeutics AB) Institutional Ownership : 10.74% (As of Sep. 21, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Infant Bacterial Therapeutics AB's institutional ownership is 10.74%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Infant Bacterial Therapeutics AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Infant Bacterial Therapeutics AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Infant Bacterial Therapeutics AB Institutional Ownership Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB Institutional Ownership Chart

Infant Bacterial Therapeutics AB Historical Data

The historical data trend for Infant Bacterial Therapeutics AB can be seen below:

	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31
Institutional Ownership	10.26	10.16	10.20	10.20	10.65	10.65	10.88	10.95	11.01	11.01

Infant Bacterial Therapeutics AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Infant Bacterial Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

IBT B:Sweden 9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.

Infant Bacterial Therapeutics AB Headlines

No Headlines